Affomix Corporation (Branford, CT) developed technology to permit high throughput production and screening of antibodies against virtually all human proteins, both as encoded and post-translationally modified, and was founded, in part, on research licensed by Affomix that was developed at a large pharmaceutical company.  Two Yale scientists were co-founders.   Elm Street partner and Affomix co-founder, Mike Sherman, served as President from the company‚Äôs start in 2006. In addition to co-founding the company and providing seed financing, Elm Street participated in a $7 million Series A funding in January, 2008. Co-investors included Four Seasons and Connecticut Innovations. Elm Street was represented on the board by Mike Sherman, Greg Gardiner, and Rob Bettigole (as an observer).  In July of 2010, Affomix was purchased by Illumina, Inc., a NASDAQ listed company (ILMN).